Beware the BCG failures: A review of one institution's results

European Urology

Volumn 42, Issue 6, 2002, Pages 542-546

  Lockyer, C Richard W ^a   Sedgwick, James E C ^b   Gillatt, David A ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Bacille Calmette Guerin; Disease progression; Prognosis; Recurrence; Transitional cell carcinoma

Indexed keywords

BCG VACCINE; IMMUNOLOGICAL ADJUVANT;

ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER MORTALITY; CYSTOSCOPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PATIENT COUNSELING; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA; TREATMENT FAILURE; BLADDER TUMOR;

ADJUVANTS, IMMUNOLOGIC; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; FOLLOW-UP STUDIES; HUMANS; TREATMENT FAILURE; URINARY BLADDER NEOPLASMS;

EID: 0036904886     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00491-8     Document Type: Article

References (10)

1. Parmar MK, Freedman LS, Hargreave TB, Tolley DA. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: Report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol 1989;142(2 Pt 1):284-8.
2. Pagano F, Garbeglio A, Milani C, Bassi P, Pegoraro V. Prognosis of bladder cancer. I. Risk factors in superficial transitional cell carcinoma. Eur Urol 1987;13(3):145-9.
3. Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992;19(3):573-80.
4. Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG. Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol 1986;135(2):272-4.
5. Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ. 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999;161(4):1124-7.
6. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, Hawkins IR. Superficial bladder cancer: Progression and recurrence. J Urol 1983;130(6):1083-6.
7. Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 1987;137(2):220-4.
8. Merz VW, Marth D, Kraft R, Ackermann DK, Zingg EJ, Studer UE. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guerin for carcinoma in situ of the bladder. Br J Urol 1995;75(2):180-4.
9. Solsona E, Iborra I, Dumont R, Rubio-Briones J, Casanova J, Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 2000;164(3 Pt 1):685-9.
10. Lamm DL, Blumenstein BA, Crissman JD, Montie JE. Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. J Urol 2000;163(4):1124-9.